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ABSTRACT 
Objective: To evaluate the potential role of tramadol treatment with respect to CYP2D6 polymorphism in reducing the incidence of adverse drug 
reactions. 
Methods: The study comprised 246 patients of PHN receiving tramadol treatment. Adverse drug events during the time of the study were recorded 
by the physician. All samples were analyzed for CYP2D6 (*2, *4 and *10) polymorphism using PCR-RFLP method. 
Results: The CYP2D6 polymorphism did not find significantly among onset at age, genders and weight in non-responders and responders. The 
CYP2D6*4 polymorphism was significantly associated with somnolence (p=0.009), dizziness (p=0.007), local site reactions (p=0.015), headache 
(p=0. 039), and nausea and vomiting (p=0. 017). The dizziness (p=0. 029) and headache (p=0. 004) were found associated with CYP2D6*2 both the 
groups. No associations were observed between adverse events compared with CYP2D6*2 and CYP2D6*10 polymorphisms (p>0.05).  
Conclusion: CYP2D6*4 polymorphism may be as important drug toxicity marker predictors of experiencing adverse drug reactions as PHN patients 
undergoing tramadol treatment.  
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INTRODUCTION  
Adverse drug reactions (ADRs) are a significant cause of morbidity 
and mortality. The person-to-person variability of drug response is a 
major problem in clinical practice and drug development [1]. The 
potential risk factors for drug in efficacy or toxicity include drug–
drug interactions, the patient’s age, sex, or other disease factors, and 
lifestyle variables such as smoking and alcohol consumption. All 
these factors, should be evident for the physicians. In addition, it has 
become clear in recent years, that genetic factors may also 
significantly modify drug responses or increase the risk for ADRs[2]. 
The neuropathic pain is very challenging to manage because of the 
heterogeneity of its aetiologies, symptoms and underlying 
mechanisms [3]. It is often difficult to treat, because it is resistant to 
many medications and/or because of the adverse effects associated 
with effective medications. A number of drugs are used to manage 
neuropathic pain, including antidepressants [4], anticonvulsant 
drugs [5], opioids especially tramadol [6,7,8,9] and topical 
treatments such as capsaicin[10] and lidocaine [11]. Many people 
require treatment with more than one drug but the correct choice of 
drugs and the optimal sequence for their use have been still unclear.  
Tramadol is an analgesic drug which is used for neuropathic pain 
like post herpetic neuralgia (PHN) [6-9]. Consequently, there is a 
subset of patients who develop drug-induced adverse side-effects 
such as somnolence, dizziness, the local site reaction, headache, 
hypotension, nausea and vomiting [8,12-16]. Therefore, safe and 
effective treatments are needed for PHN patients. Tramadol is 
metabolized by CYP2D6 to generate a pharmacologically active 
product, the analgesic opioid receptor agonist O-desmethyltramadol. 
Variability in response is, therefore, closely related to the CYP2D6 
genotype [17]. The polymorphic drug metabolism in a population 
identifies, the proportion of individuals differing inability to 
metabolize certain drugs and who therefore, are likely to react 
differently or adversely to drugs [18]. According to the activity of the 
CYP2D6 enzyme, the polymorphism of the enzyme results in poor 
metabolizers (PMs), intermediate metabolizers (IMs), extensive 
metabolizers (EMs), and ultra extensive metabolizers (UMs) of 
CYP2D6 drugs [19]. Thus, elevated drug levels in PMs and UMs might 
lead to increased side effects during pharmacological treatment. 
The goal of our study is to predict CYP2D6 response with respect to 
tramadol treatment and improves drug response in the personalized 
medicine in individual patients and reduce adverse drug effects. 
Here, the aim of the current study, tramadol treated PHN patients 
having adverse drug events comparing with CYP2D6 (*2,*4 and *10) 
polymorphism. 
MATERIALS AND METHODS 
Study design 
The study was a prospective, non-responders versus responders in 
the symptomatic treatment of PHN, and consisted of oral 
administration of tramadol (short acting) for 4 weeks with day 0 
(baseline) considered as a baseline. According to the study design, a 
total of 270 patients were initially enrolled for the treatment of 
which 15 patients did not fit the inclusion criteria and 9 patients did 
not receive tramadol therapy. Patients those reporting less than 
50% pain relief categorized as “non-responders” (72 males and 51 
females) and patients who had achieved 50% pain relief 14 days of 
tramadol treatment as “responders” (76 males and 47 females). The 
study was conducted in association with the Pain Clinic of 
Department of Anesthesiology, Department of Dermatology, 
Environmental Biochemistry and Molecular Biology Laboratory, 
Department of Biochemistry and Department of Pharmacology at 
University College of Medical Sciences (University of Delhi) & Guru 
Teg Bahadur Hospital, New Delhi- 110095, India during the period 
January 2009 to January 2012. The study was approved by the 
Institutional Ethics Committee –Human Research. Written informed 
consent was obtained from all patients. 
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The duration of oral tramadol treatment was 4 weeks from day 0 
(inclusion visit) to day 28 (the day before the end visit). At 0 days 
(baseline phase), patients rated the intensity of PHN pain over the 
previous 24 hours using an 11-point NRS ranges from 0 as no pain in 
10 as worst possible pain. The daily dose of tramadol was increased, 
depending on the therapeutic response and on treatment 
acceptability, from one tablet (50mg) per day to four tablets 
(200mg) per day. Dose incrementation was performed stepwise in 
accordance with the following schedule: at least 48 h between step 1 
(one tablet =50mg per day) and 2 (two tablets = 100mg per day), at 
least 72 h between step 2 and 3 (three tablets= 150mg per day) or 
between step 3 and 4 (four tablets = 200mg per day) in patients 
aged at the maximum 70 years. On the other hand, the dose 
incrementation schedule for patients aged more than 70 years 
consisted of a time interval of 72 h between step 1 and 2, and at least 
120 h between step 2 and 3. In patients, not responding to oral 
medications rescue analgesia was given in the form of topical 
application of capsaicin 0.05% and/or doxepin 3.33% cream, four 
times a day after two weeks in the painful affected dermatomes. The 
adverse drug reaction was recorded by the physician. 
Inclusion criteria 
The study participants included men and women (in age group of 
20-80 years) of Indo-Aryan ethnicity and had PHN defined as pain 
present for more than 3 months after healing of a herpes zoster skin 
rash. Patients were considered eligible if their pain was at least 4 on 
the 11 point numerical rating scale (NRS) which includes three of 
the constituent symptoms of neuropathic pain namely severe 
burning, shooting pain, paresthesia and precipitation of pain on 
touch of a pledget of cotton (allodynia) during the base-week 
preceding randomization. All patients of PHN were having sharp, 
shooting pain that is unresponsive to non-steroidal anti-
inflammatory drugs (NSAIDs). Patients receiving NSAIDs were 
instructed to stop these drugs three days prior to the 
commencement of treatment with tramadol. 
Exclusion criteria 
Patients who presented with symptoms or past history of 
depression, immune-depression, seizures, illicit drug abuse or 
central nervous system depressant drug abuse, severe hepatic, renal, 
cardiac or respiratory pathology, hypersensitivity to tramadol or to 
opioids were excluded from the study. Patients likely to receive any 
treatment known to interfere with the studied drug or with the 
study design such as neurological surgery, anesthetic blocks, local 
treatments of pain, antidepressants, anticonvulsants, anti-vitamin K, 
(enzymatic inducers), were also excluded. Patients with any history 
of diabetes mellitus, HIV, malignancy, haematological or liver 
disease, psychiatric illness, alcohol abuse or those receiving 
corticosteroids and immunosuppressive drugs were not included. In 
addition, patients having WBC <2500 mm3, neutrophil count <1500 
mm3 or platelet count <100 x 103 mm3 were also excluded. Pregnant 
or breast- feeding women and women who risked becoming 
pregnant during the study period were not included. 
Genotyping 
5 ml of blood was taken out from each patient and collected in EDTA 
coated vials. DNA was extracted using commercially available DNA 
extraction kit (Hi- Media Mini preparation kit, Hi- Media 
Laboratories Pvt. Ltd. Mumbai, India). The Polymerase Chain 
Reaction-Rescticon Fragment Lengh Polymorphism (PCR-RFLP) was 
done by digesting PCR product with their respective restriction 
enzyme that determines the polymorphic site depending on the 
presence or absence of its recognition sequence (Table 1). The UMs, 
EMs, IMs and PMs patients were categorized based on genetic 
analysis (PCR-RFLP Method) [20,21,8,9]. 
 
Table 1: Primer sequences of CYP2D6 alleles and PCR-RFLP detection method using their respective restriction enzymes 
S. No. CYP2D6 alleles Primer Sequences Detection Method 













Statistical analysis  
The descriptive statistics were expressed as number and percentage. 
The Chi - square test was used to find the association between an 
onset at ages, genders, adverse events with different metabolizers of 
CYP2D6 polymorphism. Odds ratios were calculated to test the 
significance of genotype association with the occurrence of PHN. p 
value <0.05 was taken as significant. The frequency of EMs genotype 
was calculated by adding the total of the EMs genotypes and half of 
the IMs genotypes, which was divided by the total number of 
individuals, the PMs genotype allele frequency was calculated by 
subtracting E allele frequency from 1 (P =1-E). 
RESULTS 
The study group consisted of 246 patients of PHN (148 males and 98 
females) who fulfilled the inclusion/exclusion criteria. 
Demographic characterstics 
Both the groups (123 non- responders and 123 responders) of PHN 
patients compared with respect to sex, age, weight, duration of 
disease and gender ratio were found no significant (p >0.05). The 
total gender means non-responders were 53.33±12.47 (males 
53.94±13.24; females 52.45±11.35) and total mean responders was 
52.23±12.08 (males 53.50±12.72; females 50.17±10.79.33). The 
mean age (in years) of patients in non-responders was 53.33±12.47 
and in responders were 52.23±12.08. The mean weight (in kg) in 
group non-responders was 56.28±10.95 and in responders was 
51.23±11.45. The mean duration of disease (in months) of patients 
in non-responders were 4.79±3.48 and in responders were 
4.23±4.47. The gender ratio (Male: Female) in non-responders and 
responders were 72:51 and 76:47 respectively.  
Adverse events in non responders and responders 
Clinically, somnolence was noticed 38 (30.8%) in non- responder 
patients and 27 (21.95%) responder patients. Dizziness was 
experienced by 18 (14.63%) patients in responders and 36 (29.2%) 
patients in non- responders lasted from 2-3 days and then subsided. 
Thirty one non-responders (25.2%) and 18 (14.63%) patients in 
responders suffered local site reaction. Headache was seen in 30 
(24.3%) non- responders and 20 (16.26%) patients in responders. 
However, hypotension was observed 46 (37.3%) in non- responders 
and 19 (15.44%) patients in responder. Fifty (40.6%) patients in 
non- responders and 18 (14.63%) patients in responders had 
nausea and vomiting (Table 2). 
Onset at age with respect to CYP2D6 polymorphism  
The primary age of onset for PHN patients was categorized 
according to age wise groups (20-40 years), (41-60 years) and (61-
80 years) respectively. UMs were found in *2 and *4 alleles and not 
in *10 allele. Higher numbers and percentage of UMs were found in 
the age (41-60 years) [ Non responders - 3 (75%) and Responders 
(2 (66.7%)] in *2 allele whereas in *4 allele in the responders group 
5 (62.5%) UMs were observed. Hence, a significant linear trend was 
not found between the age of the PHN patients and the UMs with 
respect to the CYP2D6 polymorphism (p>0.05). EMs were higher 
in numbers and percentage with respect to *2, *4 and *10 alleles 
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in both the group of PHN patients. In the age wise groups (20-40 
years) and (61-80 years) a reduced number of EMs were found 
as compared with age (40-60 years). IMs also showed the same 
pattern just like EMs. The PMs was found in all age groups. 
Higher numbers of PMs were found in the age group (41-60 
years) in *2 allele but very less numbers were observed in *4 
and *10 alleles. No linear trends were observed between the age 
wise groups of PHN patients and PMs with respect to CYP2D6 
polymorphism. None of the values was found to be statistically 
significant (p>0.05). Further, no significant differences were 
observed in EMs and PMs genotype allele frequencies (p>0.05) 
(Table 3). 
 
Table 2: Adverse events in non responders and responders 
Adverse events Non-responders(n=123) Responders(n=123) 
Somnolence 38(30.8%) 27(21.95%) 
Dizziness 36(29.2%) 18(14.63%) 
Local site reaction 31(25.2%) 18(14.63%) 
Headache 30(24.3%) 20(16.26%) 
Hypotension 46(37.3%) 19(15.44%) 
Nausea and vomiting 50(40.6%) 18(14.63%) 
N= numbers; All adverse events expressed in numbers and percentage 
 
Table 3: Onset at age and CYP2D6 polymorphism 
Ages Metabolizers CYP2D6*2 allele CYP2D6*4 allele CYP2D6*10 allele 
  NR R NR R NR R 
20-40 years UM n(%) 1(25%) 1(33.3%) 0(0%) 1(12.5%) 0(0%) 0(0%) 
41-60 years 3(75%) 2(66.7%) 0(0%) 5(62.5%) 0(0%) 0(0%) 
61-80 years 0(0%) 0(0%) 0(0%) 2(25.0%) 0(0%) 0(0%) 
20-40 years EM n(%) 11(19.6%) 15(23.1%) 14(16.9%) 20(21.7%) 16(19.8%) 18(20.5%) 
41-60 years 26(46.4%) 34(52.3%) 36(46.8%) 47(51.1%) 41(50.6%) 45(51.1%) 
61-80 years 19(33.9) 16(24.6%) 28(36.4%) 25(27.2%) 24(29.6%) 25(28.4%) 
20-40 years IM n(%) 8(26.7%) 7(17.1%) 10(29.4%) 4(19.0%) 7(23.3%) 5(16.7%) 
41-60 years 13(43.3%) 19(46.3%) 18(52.9%) 13(61.9%) 12(40.0%) 18(60.0%) 
61-80 years 9(30.0%) 15(36.6%) 6(17.6%) 4(19.0%) 11(36.7%) 7(23.3%) 
20-40 years PM n(%) 5(15.2%) 2(14.3%) 2(18.2%) 0(0%) 2(16.7%) 2(40.0%) 
41-60 years 17(51.5%) 11(78.6%) 4(36.4%) 1(50.0%) 6(50.0%) 3(60.0%) 
61-80 years 11(33.3%) 1 (7.1%) 5(45.5%) 1(50.0%) 4(33.2%) 0(0%) 
 Total 123 123 123 123 123 123 
Pearson’s Chi-square Test 0.763 0.268 0.230 0.906 0.894 0.542 
Allele Frequencies  
EM genotypes 
20-40 0.6 0.36 0.72 0.88 0.78 0.82 
41-60 0.652 0.449 0.762 0.810 0.796 0.796 
61-80 0.602 0.397 0.794 0.843 0.782 0.782 
PM genotypes 
20-40 0.74 0.26 0.28 0.12 0.22 0.18 
41-60 0.659 0.310 0.226 0.189 0.203 0.18 
61-80 0.734 0.265 0.205 0.159 0.269 0.109 
UM- Ultra metabolizers; EX- Extensive metabolizers; IM- Intermediate metabolizers; PM- Poor metabolizers; NR- Non responders; R- Responders; 
All values are expressed in numbers and percentage 
 
Table 4: Genders and CYP2D6 polymorphism 
 CYP2D6 Polymorphism 
Genders Metabolizers  CYP2D6*2 allele CYP2D6*4 allele CYP2D6*10 allele 
  NR R NR R NR R 
Males UM n(%) 2(2.8%) 2(2.6%) 0(0%) 3(3.9%) 0(%) 0(%) 
Females 2(3.9%) 1(2.1%) 0(0%) 5(10.6%) 0(%) 0(%) 
Males EM n(%) 30(41.7%) 38(50.0%) 43(60.6%) 60(78.9%) 44(61.1%) 55(72.4%) 
Females 26(51.0%) 27(57.4%) 34(27.9%) 32(68.1%) 37(72.5%) 33(70.2%) 
Males IM n(%) 19(26.4%) 26(34.2%) 20(28.2%) 11(14.5%) 23(31.9%) 19(25.0%) 
Females 11(21.6%) 15(%) 14(27.9%) 10(21.3%) 7(13.7%) 11(23.4%) 
Males PM n(%) 21(29.2%) 10(13.2%) 8(11.3%) 2(2.6%) 5(6.9%) 2(2.6%) 
Females 12(23.5%) 4(8.5%) 3(5.9%) 0(0%) 7(13.7%) 3(6.4%) 
Total 123 123 123 123 123 123 
Pearson’s Chi-square test 0.723 0.818 0.567 0.214 0.048 0.590 
Allele Frequencies 
Males EM genotypes 0.548 0.671 0.746 0.875 0.778 0.848 
 PM genotype 0.451 0.328 0.253 0.151 0.229 0.151 
Females EM genotypes 0.671 0.734 0.803 0.787 0.794 0.840 
 PM genotype 0.328 0.265 0.196 0.212 0.205 0.202 
UM- Ultra metabolizers; EX- Extensive metabolizers; IM- Intermediate metabolizers; PM- Poor metabolizers; NR- Non responders; R- Responders; 
All values are expressed in numbers and percentage 
Number of PMs was observed in male patients as compared to females. Difference in both EMs and PMs genotype was observed in males and 
females in both the groups i. e. Non-responders and responders (Table 4). 
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Table 5: Adverse effects (somnolence, dizziness and local site reactions) and CYP2D6 polymorphism,  
Group CYP2D6*2 allele CYP2D6*4 allele CYP2D6*10 allele 
Somnolenc
e 
UM EM IM PM Total UM EM IM PM Total U
M 
EM IM PM Total 
N
R 










































































































































































































p=0.029 p=0.007 p=0.338 
Local site reactions 
N
R 
































































































p=0.258 p=0.015 p=0.838 
UM- Ultra metabolizers; EX- Extensive metabolizers; IM- Intermediate metabolizers; PM- Poor metabolizers; NR- Non responders; R- Responders; 
All values are expressed in numbers and percentage 
 
Genders with respect to CYP2D6 polymorphism  
Both the group of PHN patients were compared with CYP2D6 (*2,*4 
and *10 alleles) polymorphism according to genders. UMs was 
observed in *2 and *4 alleles whereas it was not found in *10 allele. 
Higher numbers of males (EMs and IMs metabolizers) were found as 
compared to females of CYP2D6 polymorphism. The PMs was found in 
both groups with respect to *2, *4 and *10 alleles. Non-responders 
group consisted of higher numbers of PMs as compared with the 
responders group in *2, *4 and *10 alleles in both the genders. Higher 
Adverse effects with respect to CYP2D6 polymorphism 
Somnolence, dizziness and local site reactions 
PHN patients experiencing the various adverse effects. The 
somnolence was observed in 65 patients and did not find an 
association with *2 (p=0. 206) and *10 (p=0. 702) polymorphism 
whereas it was strongly associated with *4 (p=0. 009) polymorphsim. 
The total 54 patients had dizziness, it was experienced by 36 
patients in the non repsonders and half the number (18) in the 
responders group. The dizziness types of adverse effect was 
observed strongly associated with *2 (p= 0.029) and *4 (p= 0.007) 
polymorphism but not with 10* polymorphism (p= 0.338). The local 
site reactions were observed in 31 non-responders and only 18 
responders. Only *4 polymorphism was (p=0. 015) significantly 
associated with local site reactions (Table 5).  
Headache, hypotension and nausea and vomiting 
The headache was significantly associated with the *2 (p=0.004) and 
*4 (p=0.030) polymorphism whereas no significant association 
(p=0.343) was observed with *10 polymorphsim. Hypotension was 
not significantly associated with CYP2D6 polymorphism. The *4 allele 
showed significant (p=0.017) association with nausea and 
vomiting whereas *2 (p=0.360) and *10 (p=0.608) polymorphisms 
were not associated with this adverse effect (Table 6). 
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Rescue analgesia with CYP2D6 polymorphism 
The one hundred and thirty five patients were required rescue analgesia 
showed significant association with *2 (p=0. 023) and *4 (p=0. 002)  
 
polymorphism whereas *10 (p=0. 179) polymorphism having 
insignificant association with rescue analgesia (p>0.05) (Table 7).  
 
Table 6: Adverse effects (headache, hypotension and nausea and vomiting) and CYP2D6 polymorphism 
Group CYP2D6*2 allele CYP2D6*4 allele CYP2D6*10 allele 
Headache UM EM IM PM Total UM EM IM PM Total UM EM IM PM Total 
N
R 
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40.0%  40.0% 
Pearson’s chi 
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%  
36.8%  25.0%  29.2% 
Pearson’s Chi-
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p=0.789 p=0.132 p=0.686 
Nausea and vomiting 
N
R 































































6.2%  .0%  26.5% - 25.5
%  
31.6%  .0%  26.5% 
Pearson’s chi-
square 
p=0.360 p=0.017 p=0.608 
UM- Ultra metabolizers; EX- Extensive metabolizers; IM- Intermediate metabolizers; PM- Poor metabolizers; NR- Non responders; R- Responders; 
All values are expressed in numbers and percentage 
 
Table 7: Rescue analgesia and CYP2D6 polymorphism 
Rescue Analgesia Metabolizers CYP2D6*2 allele CYP2D6*4 allele CYP2D6*10 allele 
  NR R NR R NR R 
No UM n(%) 0 (0%) 2(1.8%) 0(0%) 7(6.3%) 0(0%) 0(0%) 
Yes 4(3.3%) 1(8.3%) 0(0%) 1(8.3%) 0(0%) 0(0%) 
No EM n(%) 0(0%) 57(51.4%) 0(0%) 82(73.9%) 0(0%) 79(71.20%) 
Yes 56(45.5%) 8(66.7%) 77(63.1%) 10(83.%) 81(65.90%) 9(75.00%) 
No IM n(%) 0(0%) 39(35.1%) 0(0%) 21(18.9%) 0(0%) 28(25.20%) 
Yes 30(24.4%) 2(16.7%) 34(27.9%) 0(0%) 30(24.40%) 2(16.70%) 
No PM n(%) 0(0%) 13(11.7%) 0(0%) 1(0.9%) 0(0%) 4(3.60%) 
Yes 33(26.8%) 1(8.3%) 11(9.0%) 1(8.3%) 12(9.80%) 1(8.30%) 
Total  123 123 123 123 123 123 
Pearson’s Chi square test p=0.023 p=0.002 p=0.179 




In the current study, adverse events of tramadol relationship with 
CYP2D6 polymorphsim has not been studied in PHN patients in 
Indian population. In our previous study, reported that treatment 
with tramadol 50 mg to 200 mg per day was associated with 
significant pain reduction in terms of enhanced pain relief, reduced 
sleep interference, greater global improvement, diminished side-
effect profile, and improved quality of life in PHN patients [7] 
Previous genetic studies also showed CYP2D6*4, and CYP2D6*2 
polymorphisms may not be a predictor of treatment outcome in 
patients with PHN receiving tramadol therapy [8,9].  
In the present study found that adverse events encountered in our 
study, due to tramadol therapy in both groups most common adverse 
effects such as somnolence, dizziness, local site reaction, headache, 
hypotension and nausea and vomiting. Dizziness and somnolence 
were the most common side effects of tramadol treatment, but could 
be tolerated by patients, even though they may have persisted 
throughout the major portion of the treatment period. The other side 
effects to be observed were mainly dry mouth and constipation mainly 
due to the effect of oral tramadol, which were relieved 
symptomatically. All the possible side effects were asked for which are 
enumerated in adverse drug effects. The greater improvement in 
endpoint means pain scores of the tramadol-treated PHN patients 
remained significant in responders as compared non-responders. Our 
previous prelimanry results also same type of clinically adverse events 
observed after the treatment of tramadol of PHN patients [8,9]. 
The most common adverse effects of tramadol are nausea, vomiting, 
dizziness, fatigue, sweating, dry mouth, drowsiness and orthostatic 
hypotension. In a summary of data from phase II–IV and post-
marketing studies, as well as from spontaneous reports including 
over 21,000 patients, the frequency of side effects was estimated to 
be 1–6% [12]. In an open study of 7,198 patients with chronic pain, 
adverse effects were noted in 16.8% of patients; 68.9% of patients 
had mild adverse effects, 22.1% had adverse effects of severe 
intensity, and there was no data for 9% of patients. The most 
frequent adverse effects were unspecific CNS irritation and signs of 
coordination disorders (7.1%), dizziness (5.3%), nausea (4.8%), 
sedation (2.4%), dry mouth (2.2%) and vomiting (0.8%). At least 
some of the adverse effects might have been evoked by tramadol’s 
interaction with concomitant drugs, which were administered to 
45% of patients receiving tramadol [22]. In a post-marketing study, 
controlled release tramadol was administered to 3,153 patients with 
chronic pain of different origins; adverse effects were noted in 6.5% 
of patients, with the most frequent effects being nausea (3.4%), 
dizziness (1.5%) and vomiting (1.1%). Boureau et al. [6] was found 
that nausea (12.5%) and constipation (4.7%) in the tramadol group 
and nausea (3.2%) in the placebo group. The side effects are reported 
of tramadol are nausea, vomiting, sweating, dry mouth, dizziness and 
sedation [23]. According to Lehmann et al. [13] adverse events 
occurring during the treatment period were dizziness (3%), headache 
(3%), nausea (6%), vomiting (6%), sweating (21%), and dry mouth 
(18%). In a study of hospitalized patients, Follin and Charland [14] 
reported that higher incidence of adverse effects was found: dizziness 
(26–33%), headache (18–32%), nausea (24–40%), vomiting (9–17%), 
sweating (6–9%), and dry mouth (5–10%). 
In this study, we did not find an onset of age, genders and weight 
related adverse events when compared with CYP2D6 polymorphism. 
Earlier reported, CYP2D6*4 and CYP2D6*2 genotype–phenotype 
distribution, all adverse events did not correlated with ages-at-
onset, genders and weight [8,9]. ADRs occur by a number of 
mechanisms, few of remain unclear, but several risk factors have 
been identified. Older age has often been identified as important risk 
factors [24-26]. A sevenfold increase in an occurrence of ADRs from 
3% to 21% has been shown to occur between patients aged 20–30 
years and 60–70 years [27]. Patients at the extremes of age are at 
increased risk of ADRs for several reasons. In the elderly, multiple 
medications are commonly taken to treat co-existing pathologies. 
Therefore, the risk of an ADR arising per se or from drug 
interactions is increased. Although older patients are generally at 
higher risk of adverse drug reactions, due to age-associated 
differences in pharmacokinetic and pharmacodynamic drug 
properties will change in older age. 
Sex is an important determinant of drug use and drug response. 
Women tend to have a higher risk of adverse drug reactions with a 
1.5 to 1.7-fold higher risk as compared with men [28-30]. Sex 
differences in pharmacology are complicated by the large variety of 
drugs, indications for use, and pharmacokinetic and 
pharmacodynamic differences between the sexes [31-34]. More data 
on drug response in women are needed. Although the authorities 
emphasized the importance of including more women in clinical 
trials as early as 1986, women are still under-represented in clinical 
research nowadays [35-37]. The policies and guidelines, set up by 
the National Institute of Health (NIH), Food and Drug Administration 
(FDA), and the European Medicines Agency (EMA), have 
unfortunately not resolved this inequality [38-40].  
The effect of a drug on the body weight depends on the combination 
of pharmacokinetic factors. Women have a different volume of 
distribution and clearance than men, which could result in 
differences in effective drug concentrations [31-34,41]. Female 
patients, being generally lighter in weight and smaller in build than 
their male counterparts but usually receiving the same drug doses, 
had been demonstrated to be more prone to ADRs in some studies 
[42,28]. This is most probably attributable to the exposure to higher 
dose per body weight for the females. Gan et al. [15]found that, the 
metabolizers (UMs, EMs, IMs and PMs), there was no difference in 
terms of age, body weight and duration of study. Using Fisher’s Exact 
test, there was also no difference in terms of sex, smoking status 
among the group, indicating that these factors did not confound the 
pharmacokinetics analysis.  
In the present study, no significant association was found between 
the adverse events (somnolence, local site reactions, hypotension, 
nausea and vomiting) when compared with the *2 and *10 
polymorphism. The adverse events such as (dizziness, and 
headache) founded a significant association with *2 polymorphism. 
All adverse events were found highly significant with *4 
polymorphism. In our four weeks, the randomized trial study was 
found that, no serious adverse effects were observed. In our 
previously reported that, based on genetic model CYP2D6*4 
polymorphism using the adverse events after treatment of tramadol. 
All adverse events found when comparing the CYP2D6*4 allele in 
EMs, IMs and PMs were nonsignificant (p>0.05). This may be due to 
the less sample size [8] and also all, adverse events compared with 
CYP2D6*2 polymorphism with EMs, IMs, and PMs show none to be 
significant (p>0.05). This may be diiference in total numbers of 
patients calculated based on yes or no adverse events/in both the 
grups of non-responders and responders [9]. 
Kim et al. [35] found that, with respect to CYP2D6 activity levels, 
EM having activity score 2.0 or 1.5 and IM having 1.0 or 0.5. IMs 
participants had 3.4-fold lower odds of nausea/vomiting than 
EM participants. Because the plasma concentration of O-
desmethyltramadol is correlated with CYP2D6 activity level [17]. 
The risk of nausea/vomiting could be attributed to O-
desmethyltramadol. Gan et al. [15] was observed that twenty-
seven percent of the patients were IM and 2.9% were UMs; the 
remaining 70% were EMs. However, the analgesic effects of 
tramadol were not measured adequately among postoperative 
patients to establish its full therapeutic effect. There were 
significant differences in the adverse-effect profiles amongst the 
various genotype groups, with the IMs group experiencing more 
adverse effects than the EMs, and the EMs having more adverse 
effects than the UMs. Generally in case of UMs, Leppert et al.[43] 
are avoided tramadol administration in patients with UM 
genotypes and renal impairment. Patients being CYP2D6 UMs are 
at risk for toxic responses to tramadol treatment. Thus, a case 
report described a man with renal insufficiency and a CYP2D6 
UMs genotype that developed postoperative respiratory 
depression while receiving tramadol [16]. CYP2D6 UMs patients 
have high plasma levels of O-desmethyltramadol and better pain 
control than EMs, but UMs also experience a higher frequency of 
nausea [44]. The UMs genotype is thought to be present in 
approximately 5% of people in North America and Middle Europe, 
7–12% of people in the Mediterranean, 21% of people in Saudi 
Arabia and 29% of people in Ethiopia[16]. 
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The frequency of PMs has been reported to be as low as 0–1% in 
South-East Asian populations [45-46]. A higher incidence of adverse 
effects is expected among the PMs group, as reported by Rau et 
al.[47] who have investigated antidepressants and CYP2D6 
polymorphism. Earlier reports which found, no relationship 
between CYP2D6 *1, *3, *4, *5, *6 and *7 genotypes and the number 
and severity of adverse drug effects [48-49]. Blonk et al. [50] have 
also observed that CYP2D6*4 allele is not associated with drug 
related falls in elderly people. Gan et al. [15] observed that, the 
incidence of vomiting, the IMs were found, to have a statistically 
higher incidence of adverse drug reactions when compared with the 
groups that, metabolize tramadol faster (UMs and EMs). This shows 
that the slower metabolizers of tramadol tend to experience more 
adverse effects of the drug. It was also found that, there were 
significant differences in the adverse-effect profiles amongst the 
various genotype groups, with the IMs group experiencing more 
adverse effects than the EMs, and the EMs having more adverse 
effects than the UMs. It was also observed the CYP2D6 activity may 
play an important role in determining the pharmacokinetics of 
tramadol and in predicting it’s adverse. 
In the present study, all patients in non-responders and 11 patients 
in responder used rescue analgesia. The significant improvement in 
pain intensity scores and quality of life in non-responders is mainly 
attributed to the use of rescue analgesia for 28 days rather than 
recommended tramadol therapy. The CYP2D6*2 and *4 alleles 
having significant impact with rescue analgesia whereas no 
significant impact on *10 polymorphism. The use of doxepin [51-53] 
and capsaicin, as an analgesic has been recommended for long in the 
pain management of PHN [54-57], diabetic neuropathy and surgical 
neuropathic pain[56]. A number of studies involving low-
concentration capsaicin creams (0.025% and 0.075%) as a unimodal 
modality have demonstrated efficacy in the treatment of PHN [51-
52,54]. Topical capsaicin, the doxepin cream or a combination of 
both have been shown to significantly reduce chronic neuropathic 
pain [58]. Recently in a prospective, randomized, double blind, 
placebo controlled trial, Indu et al.[59] (unpublished data) observed 
that a multimodal approach comprising of topical application of 
capsaicin (0.05 %) and Doxepin (3.33%) combination cream (4 
times a day for 4 weeks), continuous thoracic epidural infusion (for 
72 hours) and oral pregabalin (75 mg bd for 4 weeks) provided 
significant reduction in VAS scores, GPE scores and NPSI scores of 
PHN patients at days 4, 14 and 28 days follow up. Similar results 
were observed in the present study through the latter involves 
single treatment modality i. e. Tramadol. 
In the present study, CYP2D6*4 polymorphism may be as important 
drug toxicity marker predictor of experiencing adverse drug 
reactions as PHN patients undergoing tramadol treatment. More 
research is required to explain the clear CYP2D6*4 polymorphism 
related to tramadol treatment. It is also suggested that the newer 
opioid, tapentadol, which is independent of CYP2D6-mediated 
metabolism, and hence devoid of any inter-individual variation, 
should also be evaluated for its safety and efficacy in PHN patients. 
CONCLUSION 
The current approach to the identification of genetic predisposition 
to ADRs is limited. The CYP2D6*4 polymorphism strongly associated 
with development of adverse drug reactions whereas none of 
CYP2D6*2 allele and CYP2D6*10 allele did not find any associations 
with ADRs undergoing tramadol treatment of PHN patients. 
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